SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.

NCT00412334 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Copegus
DRUG: Copegus
DRUG: peginterferon alfa-2a [Pegasys]
DRUG: peginterferon alfa-2a [Pegasys]

Sponsor

Hoffmann-La Roche